Why Global Pull Incentives Matter For AMR Drugs

Tokyo Meeting Hears Views

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Pull incentive model in a global scale is necessary for the sustainability for AMR drugs, Shionogi and GARDP say.
global pull incentive model necessary for sustainability of AMR drugs, Shionogi and GARDP say • Source: Shutterstock

The sustainable supply of drugs for antimicrobial resistance (AMR) is needed on a global scale. However, this will require both pull incentive models for reimbursement and high technology for producing molecules with complex structures, while also ensuring compliance with Good Manufacturing Practice (GMP) standards. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas